Author(s)

Lelio Sabetti, Immacolata Greco, Domenico Di Lodovico, Antonio Berarducci

Eye Clinic, San Salvatore Hospital, University of L’Aquila, L’Aquila, Italy..

Purpose: The purpose of the study was to evaluate the efficacy of botulinum toxin type A (BTX-A) injection in patients with acquired VI nerve palsy. Methods: Twenty-eight patients (16 F and 12 M), mean age 36.4 +/-- 17.8 DS; range 10 - 69 years with acquired VI nerve palsy, have been treated with BTX-A injection into the ipsilateral medial rectus, at least 6 months after onset. At 6 months follow up, a paresis and a paralysis, were respectively diagnosed if the affected eye could be actively abducted or not, across the mid-line; a simple horizontal rectus muscle procedure was performed for the paresis whilst for the paralysis, both a horizontal and vertical muscle transportation procedure were required. Results: A gradual physiological recovery of the lateral rectus muscle was observed in 9 (32%) patients (GROUP I) and surgical treatment was therefore unnecessary; the remaining 19 cases (68%), of which 5 paresis (GROUP II) and 14 paralysis (GROUP III) underwent surgery and within 1 year were all restored to orthotropia. Conclusion: Botulinum toxin type-A (BTX-A) injection is an invaluable tool in the differential diagnosis between paresis versus paralysis of the VIth nerve, allowing the correct choice of surgical procedure.

Chronic Acquired VI Nerve Palsy; Botulinum Toxin Type-A

L. Sabetti, I. Greco, D. Lodovico and A. Berarducci, "Usefulness of Botulinum Toxin Type-A in the Treatment of Chronic Sixth Nerve Palsy," Open Journal of Ophthalmology, Vol. 2 No. 1, 2012, pp. 1-4. doi: 10.4236/ojoph.2012.21001.